Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
NCT06797999

First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma

Led by Adcendo ApS · Updated on 2026-01-28

270

Participants Needed

8

Research Sites

194 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to learn about the safety, tolerability and efficacy of ADCE-D01.

CONDITIONS

Official Title

First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • 18 years of age or older
  • Histologically confirmed soft tissue sarcoma with metastatic and/or unresectable disease
  • Prior treatment with at least one but no more than two lines of cytotoxic systemic therapy for metastatic/unresectable disease
  • Measurable disease according to RECIST v 1.1
  • ECOG performance status of 0 or 1
  • Life expectancy of at least 3 months
  • Male patients must agree to use barrier contraception during treatment and for 4 months after last infusion and refrain from donating sperm during this period
  • Male patients with pregnant partners must use barrier contraception or abstain from sexual activity during treatment and for 4 months after last infusion
  • Female patients must not be pregnant, breastfeeding, or be women of childbearing potential unless agreeing to use contraception during treatment and for 7 months after last infusion
Not Eligible

You will not qualify if you...

  • Systemic anticancer therapy, including investigational agents, within 4 weeks or 5 half-lives before study treatment
  • Primary brain malignancy or untreated central nervous system or leptomeningeal metastases, or symptoms suggesting CNS involvement
  • Clinically significant cardiovascular disease
  • Acute HIV 1 or HIV 2 infection
  • Active liver disease due to hepatitis B
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on chest CT scan at screening

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 8 locations

1

University of Colorado Denver

Aurora, Colorado, United States, 80208

Actively Recruiting

2

University of Miami - Sylvester Comprehensive Cancer Center

Miami, Florida, United States, 33136

Actively Recruiting

3

Memorial Sloan Kettering Cancer Center

New York, New York, United States, 10065

Actively Recruiting

4

University Of Texas MD Anderson Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

5

Universitair Ziekenhuis Leuven (UZ Leuven) - Campus Gasthuisberg

Leuven, Belgium, 3000

Actively Recruiting

6

Centre Léon Bérard

Lyon, France, 69373

Actively Recruiting

7

Universitätsklinikum Essen West German Tumor Center

Essen, Germany, D-45147

Actively Recruiting

8

Royal Marsden

London, United Kingdom

Not Yet Recruiting

Loading map...

Research Team

R

René Smrčka

CONTACT

M

Margaret McNaull

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here